U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.41%)
     
  • BTC-USD

    19,293.05
    -126.22 (-0.65%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade

·1 min read
INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of INmune Bio Inc. plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New Drug (IND) application to initiate its Phase 2 trial of its XPro Alzheimer's treatment on clinical hold. Also in the email, the FDA requested additional information around Chemistry Manufacturing and Controls (CMC) regarding the company's newly man